Glycine supplementation mitigates lead-induced renal injury in mice

Mojtaba Shafiekhani1,2
Mohammad Mehdi Ommati3
Negar Azarpira4
Reza Heidari3
Amir Ahmad Salarian1

1Toxin Research Center, Faculty of Medicine, Aja University of Medical Science, Tehran, Iran; 2Department of Clinical Pharmacy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; 3Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; 4Department of Pathology, Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Purpose: Lead (Pb) is an environmental pollutant responsible for various organ damages including renal injury. It seems that OS and associated events are crucial mechanisms of lead-induced renal dysfunction. The current study aimed to explore the potential protective effects of glycine against renal injury caused by lead in mice.

Materials and methods: Mature male mice (n=32) were allocated into four groups. The following treatment regimens were the control (vehicle-treated); Pb-acetate (20 mg/kg/day, gavage); Pb-acetate + glycine (500 mg/kg/day, IP); and Pb-acetate + glycine (1,000 mg/kg/day, IP). Pb-acetate + glycine was administered for 14 consecutive days, Pb-acetate was given first and then glycine at least 6 hours later. On day 15, the subjects were anesthetized, and samples were collected. Serum biomarkers such as BUN and serum creatinine were monitored along with formation of reactive oxygen species, lipid peroxidation, kidney GSH level, and histopathological changes.

Results: Based on the results, BUN and serum creatinine levels significantly increased following exposure to lead. Glycine supplementation (500 and 1,000 mg/kg, IP) decreased BUN and creatinine serum levels (P<0.001). Biomarkers of OS were also reduced in renal tissue following glycine therapy in Pb-exposed mice (P<0.001). Histopathological changes were observed in mice treated with lead as tubular dilation, protein cast, vacuolization, and inflammation. In this regard, glycine inhibited histopathological alterations in kidney caused by lead exposure.

Conclusion: It was found that glycine treatment significantly mitigated Pb-induced renal injury most likely through alleviating OS and the associated deleterious outcomes on the kidney tissue.

Keywords: amino acids, glycine, lead, heavy metals, oxidative stress, nephrotoxicity

Introduction

Humans are continuously exposed to lead (Pb), a toxic heavy metal, which is an environmental pollutant.1 Accumulation of lead in various organs such as bone, liver, kidney, and reproductive system is associated with deleterious effects.2-5

One of the potential adverse effects of prolonged and high-level Pb exposure is renal injury and nephropathy. Pb-induced nephropathy usually occurs as a result of prolonged exposure to this heavy metal and constant high plasma Pb level of >60 μg/dL. Meanwhile, prolonged Pb exposure at lower plasma levels could also cause nephrotoxicity.6,7 According to animal and histopathological studies, the most affected segment of kidney in Pb-induced renal injury is the proximal tubule.8 Tubular atrophy, interstitial fibrosis, hypertrophic arteriolar changes, and accumulation of inflammatory...
cells are common histological alterations in kidney tissues in experimental models of Pb nephrotoxicity.9,10

In Pb-induced nephrotoxicity, different mechanisms have been reported.7 Among these mechanisms, OS and its associated events are noteworthy, 5,11,12 which include increased reactive oxygen species (ROS) levels, biological target disruption, and defects in cellular antioxidant mechanisms.12,13 Therefore, it seems rational to use antioxidants as therapeutic options against Pb toxicity.

Glycine, an amino acid with the simplest structure, is an intricate part of protein structure. Several pharmacological properties are attributed to glycine. Interestingly, it was found that glycine supplementation could protect biological targets against a variety of xenobiotics.14–17 Some studies mentioned the nephroprotective properties of this amino acid.18 Regarding its cytoprotective activity, different mechanisms are suggested. Based on the findings, glycine can effectively reduce OS caused by xenobiotics.14–17,19

The current study aimed to evaluate the potential nephroprotective effects of glycine against Pb nephrotoxicity in an animal model.

Materials and methods

Chemicals

Glycine (2-aminoacetic acid), malondialdehyde, thiobarbituric acid, dithiobis-2-nitrobenzoic acid, GSH, 2′,7′-dichloro-Fluorescein diacetate (DCFH-DA), and EDTA were provided by Sigma-Aldrich (St. Louis, MO, USA). Trichloroacetic acid (TCA), dithiothreitol (DTT), ferric chloride hexahydrate, 2,4,6-Tris (2-pyridyl)-s-triazine (TPTZ), and Tris (hydroxy-methyl) aminomethane hydrochloride were provided by Merck (Darmstadt, Germany).

Animals and treatments

A total of 32 adult male BALB/c mice (25–30 g) were purchased from the Laboratory Animals Breeding Center, Shiraz University of Medical Sciences (SUMS), Shiraz, Iran, and kept under standard conditions (12L:12D, photo schedule; 18–22°C; appropriate ventilation, ~40% humidity) and fed ad libitum with water and commercial rodent pellets (Behparvar®, Tehran, Iran). The animal procedures were done at Pharmaceutical Sciences Research Center, School of Pharmacy, SUMS. The local ethics committee of AJA University of Medical Sciences, Tehran, Iran, approved this study (#97-01-36-17657).

The animals received humane care and were handled regarding the guidelines of the ethics committee of AJA University of Medical Sciences.

The subjects were allocated into four groups of eight mice and the following treatment regimens were introduced: the control (vehicle-treated); Pb-acetate (20 mg/kg/day, gavage); Pb-acetate (20 mg/kg/day, gavage) + glycine (500 mg/kg/day, IP); and Pb-acetate (20 mg/kg/day, gavage) + glycine (1,000 mg/kg/day, IP). Pb-acetate + glycine were given for 14 consecutive days. Pb-acetate dose was selected based on previous studies that mentioned 20 mg/kg of Pb-acetate as the nephrotoxic dose.21 Glycine was administered at least 6 hours after Pb-acetate administration. On day 15, samples were collected.

Sample collection

Mice were anesthetized (thiopental 80 mg/kg, IP) to drain blood samples from abdominal vena cava. Both kidneys were excised and weighed. Right kidneys were kept in 10% formalin for histopathological evaluations. Total antioxidant capacity, lipid peroxidation, ROS production, and GSH contents were determined in the left kidneys.

Histopathology and organ weight index

The kidney was weighed, using the following formula: Weight index = [Wet weight of organ (g)/Body weight (g)] x 100.

Buffered formalin solution (0.4% sodium phosphate monobasic [NaH2PO4], 0.64% sodium phosphate dibasic [Na2HPO4], and 10% formaldehyde in distilled water) was used to fix the kidney samples for histopathological evaluations. The kidney samples were stained with H&E followed by paraffin embedding and cutting in 5 μm sections. Tissue histopathological alterations were evaluated by a pathologist in a blind manner using a light microscope (Olympus BX41; Olympus Optical Co. Ltd, Tokyo, Japan). Early proximal tubular vacuolization, tissue inflammation, protein cast, and tubular dilation were graded as mild (+), moderate (++) or severe (+++) in each group.

Plasma biochemistry

To obtain plasma sedimentation, blood samples were drained into tubes (coated with EDTA) and then centrifuged (10,000 g, 15 minutes, 4°C). BUN and creatinine plasma levels were determined using commercially available kits (Pars Azmun®, Tehran, Iran). Plasma Pb level was measured by an atomic absorption method.

ROS formation

In total, 200 mg of kidney samples homogenized on ice in 5 mL Tris-HCl buffer (40 mM, pH = 7.4, 4°C) was mixed with 100 μL homogenized sample and 1 mL of Tris-HCl buffer.
(pH 7.4) plus 10 μL of DCFH-DA until reaching 10 μM as the final concentration. The prepared samples were incubated in the dark for 15 minutes at 37°C (Gyromax™ incubator shaker). The sample luminescence intensity was recorded with a FLUOstar Omega® multifunctional microplate reader at $\lambda_{\text{excitation}} = 485$ nm and $\lambda_{\text{emission}} = 525$ nm.

**Lipid peroxidation**
For this purpose, TBA reactive substances were applied; the reaction mixture contained 500 μL of homogenized tissue (10% w/v in KCl, 1.15% w/v), 1 mL of TBA (0.375% w/v), and 3 mL of phosphoric acid (1% w/v, pH = 2). After vigorously mixing the mixture and bain-marie heating for 45 minutes at 100°C, n-butanol (2 mL) was added following cooling of the sample. Then, the samples were centrifuged at 10,000 g for 5 minutes, followed by vigorous mixing. Finally, based on the developed color, the absorbance was measured at $\lambda = 532$ nm with an EPOCH® plate reader (BioTek, Highland Park, VT, USA).

**Total antioxidant capacity in kidney tissue**
The Ferric Reducing Antioxidant Power (FRAP) assay evaluates absorbance changes at $\lambda = 595$ nm based on the blue-colored Fe$^{2+}$, tripyridyltriazine, derived from the colorless oxidized Fe$^{3+}$ using electron-donating antioxidant activity. In order to prepare the FRAP reagent freshly, acetate buffer (10 vol, 300 mM/L, pH 3.6) was mixed with TPTZ (1 vol, 10 mM/L in 40 mM/L hydrochloric acid) and ferric chloride (1 vol, 20 mM/L). The FRAP reagent was prepared on the same day of assessment and kept in the dark. Tris-HCl buffer (250 mM Tris-HCl, 200 mM sucrose, and 5 mM DTT, pH 7.4, 4°C) was used for kidney tissue homogenization on ice. Next, 50 μL of the homogenized sample (50 μL) plus deionized water (150 μL) was added to the FRAP reagent (1.5 mL). Then, samples were incubated in the dark (37°C for 5 minutes), and the absorbance rate was read at $\lambda = 595$ nm with an EPOCH® plate reader (BioTek). The sample’s protein content was measured, using Bradford method, for data standardization.

**Kidney GSH level**
GSH levels were determined spectrophotometrically as the indicator using 5,5′-dithiobis-2-nitrobenzoic acid (DTNB). For this purpose, to homogenize kidney samples, 200 mg of tissue was mixed with 8 mL EDTA (0.04 M, 4°C) on ice. Then, 5 mL of the provided homogenate was mixed with 4 mL of distilled water (4°C) plus 1 mL TCA (50% w/v; 4°C). The mixture was vortexed and centrifuged (10,000 g, 4°C, 15 minutes). Then, the supernatant (2 mL) was added to Tris-HCl buffer (4 mL, 40 mM, pH = 8.9) plus DTNB (100 μL, 10 mM in methanol). The absorbance rate of the prepared solution was read at 412 nm with an EPOCH® plate reader (BioTek).

**Data analysis**
Data are presented as mean ± SD. Data were analyzed using one-way ANOVA with Tukey’s multiple comparison tests as the post hoc. The level of significance was set at $P<0.05$.

**Results**
There were no significant changes in the kidney/body weight ratio in the current study, when Pb-treated and control animals were compared (Figure 1). On the contrary, no significant change in the body weight of animals was detected in the
current study. Plasma level in lead was significantly higher in Pb-exposed animals compared with the controls (Figure 1). However, there were no significant changes in plasma Pb levels between glycine-supplemented and Pb-treated animals (Figure 1).

Pb exposure significantly increased plasma biomarkers in renal damage (Figure 2). BUN and creatinine plasma levels were significantly higher in the Pb-treated mice compared with the controls (Figure 2). In addition, glycine supplementation significantly reduced serum BUN and creatinine levels (Figure 2).

OS biomarkers were significantly higher in Pb-treated animals (Figure 3). A significant level of ROS in addition to an elevated level of lipid peroxidation was observed in the Pb group compared with the controls (Figure 3). The kidney GSH content and tissue antioxidant capacity were significantly reduced in the Pb group (Figure 3). OS biomarkers of renal tissue were significantly reduced following glycine therapy (500 and 1,000 mg/kg, IP) in Pb-exposed mice (Figure 3).

In Pb-treated mice, histopathological changes included tubular dilation, protein cast, vacuolization, and inflammation (Figure 4 and Table 1). Glycine therapy (500 and 1,000 mg/kg, IP) mitigated renal histopathological alterations in mice exposed to lead (Figure 4 and Table 1).

Discussion

Heavy metals are toxic environmental pollutants, and exposer to them can be detrimental. Pb is a toxic heavy metal, which possesses a wide range of adverse effects in humans. Neurological abnormalities, dysregulation of the endocrine system, different types of malignancies, bone and skeletal disorders, reproductive toxicity, as well as hepatic and renal injury have been reported in association with Pb overexposure. Pb-induced nephrotoxicity is a complication that could lead to renal failure. Since there is no safe and convenient agent against renal dysfunction caused by lead, this study aimed to investigate the potential protective effects of the amino acid glycine against Pb nephrotoxicity. This study indicated that glycine supplementation (500 or 1,000 mg/kg, IP) mitigated Pb-induced renal injury, possibly by attenuating OS and its associated complications.

Different mechanisms have been proposed for the adverse effects of Pb toward biological systems. Among these mechanisms, OS and its associated complications have a fundamental role. It has been well documented that Pb exposure is associated with significant ROS formation, defects in cellular antioxidant mechanisms, and disruption of biological targets such as cell membrane and different intracellular proteins. Pb-associated OS is also important in nephrotoxicity mechanism. Some investigations mentioned the importance of antioxidant therapy against Pb-induced renal injury. The obtained results emphasize on the importance of OS and its related consequences in the pathogenesis of Pb nephrotoxicity. In consensus with previous studies, we found that Pb exposure is associated with significant ROS formation, lipid peroxidation, kidney tissue GSH depletion, and defects in the renal antioxidant...
Figure 3 Biomarkers of OS in renal tissue of lead (Pb)-treated animals.  
Notes: ROS formation (A), Lipid peroxidation (B). Total antioxidant capacity (C), Tissue GSH level (D). Data are given as mean ± SD (n=8). *Significantly different compared with the control group (P<0.001). Asterisks indicate significantly different compared with Pb group (**P<0.01, ***P<0.001).

Abbreviations: DCF, dichlorofluorescein; Glyc, glycine; ns, not significant; Pb, plasma lead.

Figure 4 Renal histopathological alterations in the lead (Pb)-exposed mice.  
Notes: Normal renal tissue architecture is shown in the control group (A). Kidney tissue histopathological changes were revealed as inflammation (green arrow), protein cast (blue arrow), vacuolization (yellow arrow), and tubular dilation (red arrow) in Pb-exposed mice (B–D). It was found that glycine supplementation (500 and 1,000 mg/kg, E and F, respectively) blunted Pb-induced histopathological alterations in renal tissue.

Abbreviation: Pb, plasma lead.
Glycine is an amino acid with a simple structure, incorporated in protein structure. Glycine has different physiological and pharmacological features, and its anti-inflammatory, antioxidant, and osmoregulatory activities are reported in various experimental models. The impact of glycine on OS and its consequences are considered as its main cytoprotective activity. This amino acid is also a component of the GSH as a vital cellular antioxidant defense system. In the current investigation, higher levels of GSH were detected in the glycine-treated groups (Figure 3), which might be an indication for higher rate of GSH synthesis in glycine-treated animals. We found that glycine treatment significantly reduced Pb-induced OS in the kidney tissue. On the contrary, no significant increase in plasma Pb level was detected after glycine treatment (Figure 1). This might indicate that glycine is able to chelate Pb or enhance its excretion from the body (Figure 1).

Several studies showed the positive effects of glycine on mitochondria. One study showed that glycine treatment enhanced mitochondrial ATP content and prevented mitochondrial permeabilization and swelling. Glycine treatment also modulates mitochondria-mediated cell death and apoptosis. Mitochondria is an important source of ROS. Hence, a possible mechanism for the antioxidative properties of glycine might be mediated through affecting mitochondria-facilitated ROS formation. The precise effect of glycine on cellular mitochondria and its role in renal dysfunction caused by Pb exposure need further studies in order to be understood clearly.

Other organs rather than kidney might also be affected by Pb (e.g., reproductive system and the liver). Therefore, evaluating the mechanism of Pb toxicity and the protective effects of chemicals such as glycine in these organs warranted further investigations.

Glycine is an endogenous and safe chemical. Hence, this amino acid might be clinically applicable against a variety of complications such as Pb-induced renal injury. To understand the findings of the current study in clinical setting, further studies are warranted.

**Conclusion**

Based on the results, glycine therapy could significantly reduce renal injury in mice exposed to Pb and the probable mechanism is the alleviation of OS.

**Abbreviations**

BALB, Bagg Albino; BUN, blood urea nitrogen; FRAP, ferric reducing antioxidant power; GSH, glutathione; IP, intraperitoneal; OS, oxidative stress; TBA, thiobarbituric acid assay.

**Acknowledgments**

Authors acknowledge their gratitude to the Pharmaceutical Sciences Research Center (no. 17657) of Shiraz University of Medical Sciences for technical support. The authors also wish to thank Mr H Argasi at the Research Consultation Center of Shiraz University of Medical Sciences for his invaluable assistance in editing this manuscript.

**Author contributions**

MS, RH, MMO, AAS, and NA conceived and planned the experiments. RH, MMO, and AAS performed the measurements. MS, NA, and RH contributed to sample preparation and interpretation of the results. All authors contributed toward data analysis, drafting and revising the paper, gave final approval of the version to be published and agree to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Crinnion WJ. The CDC fourth national report on human exposure to environmental chemicals: what it tells us about our toxic burden and how it assist environmental medicine physicians. *Altern Med Rev*. 2010;15(2):101–109.
2. Mason LH, Harp JP, Han DY. Pb neurotoxicity: neuropsychological effects of lead toxicity. *Biomed Res Int*. 2014;2014(10):1–8.
3. Navas-Acien A, Guallar E, Silbergeld EK, Rothenberg SJ. Lead exposure and cardiovascular disease—a systematic review. *Environ Health Perspect*. 2007;115(3):472–482.
4. Rastogi SK. Renal effects of environmental and occupational lead exposure. Indian J Occup Environ Med. 2008;12(3):103.

5. Jia Q, Ha X, Yang Z, Hui L, Yang X. Oxidative stress: a possible mechanism for lead-induced apoptosis and nephrotoxicity. Toxicol Meth Methods. 2012;22(9):705–710.

6. Bernard BP, Becker CE. Environmental lead exposure and the kidney. J Toxicol Clin Toxicol. 1998;36(1–2):1–34.

7. Ekong EB, Jaar BG, Weaver VM. Lead-related nephrotoxicity: a review of the epidemiologic evidence. Kidney Int. 2006;70(12):2074–2084.

8. Song XB, Liu G, Liu F, et al. Autophagy blockage and lysosomal membrane permeabilization contribute to lead-induced nephrotoxicity in primary rat proximal tubular cells. Cell Death Dis. 2017;8(6):e2863.

9. Bertke SJ, Lehman EJ, Wurzelbacher SJ, Hein MJ. Mortality of lead smelter workers: a follow-up study with exposure assessment. Am J Ind Med. 2016;59(11):979–986.

10. Ingles JA, Henderson DA, Emmerson BT. The pathology and pathogenesis of chronic lead nephropathy occurring in Queensland. J Pathol. 1978;124(2):65–76.

11. Goyer RA. Mechanisms of lead and cadmium nephrotoxicity. Toxicol Lett. 1989;46(1–3):153–162.

12. Sudjarwo SA, Erako K, Sudjarwo GW, Koerniasari. Protective effects of piperine on lead acetate-induced nephrotoxicity in rats. Iran J Basic Med Sci. 2017;20(1):121–127.

13. Wang L, Wang H, Hu M, Cao J, Chen D, Liu Z. Oxidative stress and apoptotic changes in primary cultures of rat proximal tubular cells exposed to lead. Arch Toxicol. 2009;83(5):417–427.

14. Heidari R, Ghanbarinejad V, Mohammadi H, et al. Dithiothreitol had H. Regulation of mitochondrial function and energy metabolism: a primary mechanism of cytoprotection provided by carnosine. Trends Pharm Sci. 2018;39(1):285–291.

15. Heidari R, Jamshidzadeh AA, Niknahad H. The hepatoprotection provided by taurine and glycine against antineoplastic drugs induced oxidative stress of low-level lead exposure in men. Environ Res. 2007;105(2):256–266.

16. Rastogi SK. Renal effects of environmental and occupational lead exposure. Indian J Occup Environ Med. 2008;12(3):103–106.

17. Sommar JN, Svensson MK, Björ BM, et al. End-stage renal disease and low level exposure to lead, cadmium and mercury; a population-based, prospective nested case-referent study in Sweden. Environ Health. 2013;12(1):9.

18. Telisman S, Colak B, Pizent A, Jurasović M, Cvitković J, Cvitković P. Reproductive toxicity of low-level lead exposure in men. Environ Res. 2007;105(2):256–266.
